Tango Therapeutics has stated that an experimental combination of its drug vopimetostat and Revolution Medicines’ daraxonrasib produced encouraging early results in patients with advanced pancreatic cancer and will be advanced toward late-stage testing.
The findings come from an ongoing Phase 1/2 study evaluating vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC) or non-small cell lung cancer (NSCLC). As of May 28, 2026, 59 patients had received treatment in the study.
According to Tango, the combination of vopimetostat and daraxonrasib reduced tumors in 11 of 12 evaluable pancreatic cancer patients who had previously received treatment. The company reported a 92% objective response rate, a 100% disease control rate, and said that 90% of patients remained progression-free six months after starting treatment.
“In the first reported data from the clinical combinations of our PRMT5 inhibitor vopimetostat and RAS(ON) inhibitors, we saw extremely encouraging early results, with 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response, supporting the preclinical data showing synergistic activity of PRMT5 + RAS inhibition,” said Malte Peters, chief executive officer of Tango Therapeutics.
The study population consisted of patients with advanced disease, many of whom had undergone multiple previous treatments. More than half received the investigational combinations as third-line therapy. Liver metastases were present in 70% of patients in the pancreatic cancer cohort receiving daraxonrasib and in 77% of those receiving the zoldonrasib combination.
In the daraxonrasib arm, patients received either 200 mg or 250 mg of vopimetostat once daily together with 100 mg of daraxonrasib. At the data cutoff, 12 pancreatic cancer patients and three NSCLC patients had at least 14 weeks of follow-up and were evaluable for response. Tango reported that all three evaluable NSCLC patients achieved confirmed responses.
The company also provided results for a second treatment combination involving vopimetostat and zoldonrasib. Among 27 evaluable pancreatic cancer patients, tumors shrank in 14 patients, resulting in a 52% objective response rate. The combination produced a 74% six-month progression-free survival rate and a 96% disease control rate.
Tango stated that both treatment combinations were generally well tolerated. For the vopimetostat-daraxonrasib regimen, the most common treatment-related adverse events were rash, stomatitis or mucositis, and diarrhea. Most side effects were classified as Grade 1 or Grade 2. No treatment-related Grade 4 or Grade 5 adverse events were reported, and no patients discontinued treatment because of adverse events.
For the vopimetostat-zoldonrasib combination, the most frequently reported treatment-related adverse events were nausea and vomiting. Most were also Grade 1 or Grade 2 in severity. The company reported no treatment-related Grade 4 or Grade 5 adverse events, no dose-limiting toxicities, and no discontinuations due to adverse events.
The data were released one week after Revolution Medicines reported at the American Society of Clinical Oncology meeting that daraxonrasib doubled survival and improved quality of life in pancreatic cancer patients.
Based on the data, Tango said it intends to rapidly advance the vopimetostat and daraxonrasib combination into Phase 3 development for patients with MTAP-deleted pancreatic cancer. Subject to feedback from regulatory authorities, the company plans a randomized controlled Phase 3 trial in first-line pancreatic cancer patients carrying the MTAP deletion. Tango noted that MTAP deletions occur in approximately 40% of pancreatic cancers and 15% of lung cancers.
Tango Therapeutics has announced encouraging early clinical findings from its ongoing evaluation of the combination of Vopimetostat and Daraxonrasib in patients with pancreatic cancer. The preliminary data provide an important look into how Tango is leveraging precision medicine and targeted therapy approaches to address one of the most challenging forms of cancer.
Pancreatic cancer remains associated with poor survival outcomes and limited treatment options, making innovative therapeutic strategies a critical area of focus for the oncology industry. The latest update highlights Tango’s efforts to develop combination treatments designed to improve clinical outcomes for patients with advanced disease.
Tango Advances Precision Oncology Strategy
The newly reported results support Tango’s broader precision oncology platform, which focuses on identifying genetic vulnerabilities within cancer cells and developing therapies that specifically target those weaknesses. By combining Vopimetostat and Daraxonrasib, Tango aims to create a synergistic treatment approach capable of disrupting key cancer-driving pathways.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
